Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance ECT vs Aripiprazole in Clozapine-resistant Schizophrenia
NCT06501339Phase 4Not yet recruiting
- Sponsor
- AIIMS New Delhi
- Start
- Aug 2024
- Primary completion
- Oct 2025
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Positive and Negative Syndrome Scale at 24 weeks. Planned start Aug 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06501339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501339.